8 results on '"Hegenbart, Ute"'
Search Results
2. Allogeneic hematopoietic stem cell transplantation improves long-term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials.
- Author
-
Heinicke, Thomas, Krahl, Rainer, Kahl, Christoph, Cross, Michael, Scholl, Sebastian, Wolf, Hans-Heinrich, Hähling, Detlev, Hegenbart, Ute, Peter, Norma, Schulze, Antje, Florschütz, Axel, Volker, Schmidt, Reifenrath, Kolja, Zojer, Niklas, Junghanss, Christian, Sayer, Herbert G., Maschmeyer, Georg, Christian, Späth, Hochhaus, Andreas, and Fischer, Thomas
- Subjects
HEMATOPOIETIC stem cell transplantation ,OLDER patients ,OVERALL survival ,ACUTE myeloid leukemia ,HEMATOLOGY - Abstract
Relapse of acute leukemia is a frequent complication with uncertain outcome and poorly defined risk factors. From 1621 patients entered into two prospective clinical trials (AML02; n = 740 and AML04; n = 881), 74.2% reached complete remission (CR) 1 after induction(s) and 59 patients after additional induction ± hematopoietic cell transplantation (HCT). Of the non-refractory patients, 48.4% with a median age of 63 (range 17-85) years relapsed. Relapses occurred within 6 months after CR in 46.5%, between 7 and 18 months in 38.7%, and after 18 months in 14.8% of patients. Relapse treatment resulted in CR2 in 39% of patients depending upon age (54.5% of ≤ 60 and 28.6% of > 60 years), duration of CR1, and treatment of relapse. Overall survival (OS) was 10.9 (7.4-16.2) %, but OS after HCT ± intensive chemotherapy (ICT) was 39.3% (31.8-48.6) at 5 years and not different in younger and older patients. Donor lymphocyte infusion ± chemotherapy and ICT alone resulted only in OS of 15.4% and of 5%, respectively. Independent favorable factors for OS were long CR1 duration, and HCT, while non-monosomal disease was beneficial for OS in elderly patients. Leukemia-free survival [LFS; 24.9 (19.5-31.7) % at 10 years] was affected by similar risk factors. In a competing risk model, the relapse incidence at 5 years was 53.5 ± 3.5% and the non-relapse mortality rate 21.7 ± 2.9%. Lower relapse incidence was observed in patents with HCT, long CR1 duration, and female gender. Risk factors for non-relapse mortality were HCT in younger and type of AML in elderly patients. In conclusion, allogeneic HCT ± IC improved the results in relapsed AML in younger and elderly patients. Increasing CR2 rates and HCT frequency will be the challenge for the next years. Relapse of the disease remains the major problem. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
3. High leukemia-free survival after TBI-based conditioning and mycophenolate mofetil-containing immunosuppression in patients allografted for chronic myelomonocytic leukemia: a single-center experience.
- Author
-
Radujkovic, Aleksandar, Hegenbart, Ute, Müller-Tidow, Carsten, Herfarth, Klaus, Dreger, Peter, and Luft, Thomas
- Subjects
- *
CHRONIC leukemia , *TOTAL body irradiation , *ACUTE myeloid leukemia , *GRAFT versus host disease , *IMMUNOSUPPRESSION , *THERAPEUTIC use of antimetabolites , *TREATMENT of chronic myeloid leukemia , *ACUTE myeloid leukemia treatment , *HOMOGRAFTS , *MELPHALAN , *MYCOPHENOLIC acid , *ANTIVIRAL agents , *RETROSPECTIVE studies , *ANTILYMPHOCYTIC serum , *PROGNOSIS , *METHOTREXATE , *ANTIMETABOLITES , *KAPLAN-Meier estimator , *SECONDARY primary cancer , *HEMATOPOIETIC stem cell transplantation , *IMMUNOSUPPRESSIVE agents , *RADIOTHERAPY , *BUSULFAN , *T cells , *PROPORTIONAL hazards models , *THERAPEUTICS - Abstract
This retrospective single-center analysis studied the impact of the conditioning and the graft-versus-host disease (GVHD) prophylaxis on outcome in unselected patients allografted for chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML) secondary to documented prior CMML. A total of 44 patients (median age 61 years) allografted between 2002 and 2019 in our institution were analyzed. Fifteen patients had secondary AML. The conditioning regimen was fractionated 6-8 Gy total body irradiation (TBI) in combination with fludarabine in 33 (75%) patients. Eleven patients (25%) received alkylator-based conditioning therapy without TBI. For GVHD prophylaxis, a calcineurin inhibitor (CNI) backbone in combination with methotrexate (MTX) or mycophenolate mofetil (MMF) was applied in 21 and 23 patients, respectively. All patients allografted from an unrelated donor (UD) received antithymocyte globuline. In univariate analysis of the entire cohort, TBI-based conditioning and MMF-containing immunosuppression were associated with improved leukemia-free survival (LFS, HR 0.16, P < 0.001 and HR 0.41, P = 0.030, respectively). After stratification according to conditioning and GVHD prophylaxis into four groups (TBI-MMF [n = 17], TBI-MTX [n = 16], alkylator-MMF [n = 6], alkylator-MTX [n = 5]), TBI-MMF was associated with improved overall survival (OS) and LFS (P = 0.001 and P < 0.001, respectively). Patient and disease characteristics did not differ between the groups. The associations of TBI-based conditioning and MMF with prolonged LFS were observed across the CMML (n = 29), secondary AML (n = 15), and UD allograft (n = 34) subgroups. In summary, our study suggests that allografting based on intermediate-dose TBI conditioning and MMF-containing GVHD prophylaxis is associated with increased disease control in CMML. Larger (registry-based) studies are warranted to confirm our findings. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
4. Correction to: Allogeneic hematopoietic stem cell transplantation improves long‑term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials.
- Author
-
Heinicke, Thomas, Krahl, Rainer, Kahl, Christoph, Cross, Michael, Scholl, Sebastian, Wolf, Hans‑Heinrich, Hähling, Detlev, Hegenbart, Ute, Peter, Norma, Schulze, Antje, Florschütz, Axel, Schmidt, Volker, Reifenrath, Kolja, Zojer, Niklas, Junghanss, Christian, Sayer, Herbert G., Maschmeyer, Georg, Späth, Christian, Hochhaus, Andreas, and Fischer, Thomas
- Subjects
HEMATOPOIETIC stem cell transplantation ,ACUTE myeloid leukemia ,HEMATOLOGY ,ONCOLOGY ,OVERALL survival - Abstract
Correction to: Allogeneic hematopoietic stem cell transplantation improves long-term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials A Overall survival (OS) of patients with AML after frst relapse according to age. C Overall survival (OS) of patients with AML after frst relapse according to favorable, intermediate, and unfavorable cytogenetics. [Extracted from the article]
- Published
- 2021
- Full Text
- View/download PDF
5. Non-myeloablative allografting from human leucocyte antigen-identical sibling donors for treatment of acute myeloid leukaemia in first complete remission.
- Author
-
Feinstein, Lyle C., Sandmaier, Brenda M., Hegenbart, Ute, McSweeney, Peter A., Maloney, David G., Gooley, Theodore A., Maris, Michael B., Chauncey, Thomas R., Bruno, Benedetto, Appelbaum, Frederick R., Niederwieser, Dietger W., and Storb, Rainer F.
- Subjects
ACUTE myeloid leukemia ,LEUCOCYTES ,HOMOGRAFTS ,CYCLOSPORINE - Abstract
Summary. Many patients with acute myeloid leukaemia (AML) in first complete remission (CR1) are ineligible for allogeneic transplantation as a result of age or medical problems other than leukaemia. Eighteen patients (median age 59 years, range 36–73 years) with de novo (n = 13) and secondary (n = 5) AML in morphological CR1, who were not candidates for conventional allografting, received non-myeloablative peripheral blood stem cell transplants from human leucocyte antigen identical sibling donors after conditioning with 2 Gy total body irradiation (TBI; n = 10) or 2 Gy TBI and 90 mg/m
2 of fludarabine (n = 8). Postgrafting immunosuppression was with cyclosporine and mycophenolate mofetil. Two rejections were observed in patients not given fludarabine and one died with relapse. Overall, 10 patients died between 77 and 841 d, seven from relapse and three from non-relapse mortality (NRM). Day +100 NRM was 0% with a 1-year estimated NRM of 17%[95% confidence interval (CI) 0–35%]. The median follow-up among the eight survivors was 766 d (range, 188–1141 d). Seven of these eight survivors remain in complete remission (CR). One-year estimates of overall and progression-free survivals were 54% (95% CI 31–78%) and 42% (95% CI 19–66%) respectively. While follow-up is short, this analysis demonstrates that the procedure is sufficiently safe to be studied in a wider group of patients. [ABSTRACT FROM AUTHOR]- Published
- 2003
- Full Text
- View/download PDF
6. Outcome of patients with abnl(17p) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.
- Author
-
Middeke, Jan M., Min Fang, Cornelissen, Jan J., Mohr, Brigitte, Appelbaum, Frederick R., Stadler, Michael, Sanz, Jaime, Baurmann, Herrad, Bug, Gesine, Schäfer-Eckart, Kerstin, Hegenbart, Ute, Bochtler, Tilmann, Röllig, Christoph, Stölzel, Friedrich, Walter, Roland B., Ehninger, Gerhard, Bornhäuser, Martin, Löwenberg, Bob, and Schetelig, Johannes
- Subjects
- *
ACUTE myeloid leukemia , *CHROMOSOME abnormalities , *CANCER chemotherapy , *HEMATOPOIETIC stem cell transplantation , *GRAFT versus host disease , *CONFIDENCE intervals - Abstract
Patients with acute myeloid leukemia (AML) and abnormalities of chromosome 17p (abnl(17p)) are at high-risk of treatment failure. Poor outcomes have been reported with conventional chemotherapy. To accurately define the outcome after allogeneic hematopoietic stem cell transplantation (HSCT) in patients with abnl(17p) AML, we analyzed the results of patients with this abnormality who received an allogeneic HSCT between January 2000 and December 2010 in 1 of 4 well-defined cohorts (Fred Hutchinson Cancer Research Center, Haemato Oncology Foundation for Adults in the Netherlands, Study Alliance Leukemia, German Cooperative Transplant Study Group). Data of 201 patients with a median age of 54 years were evaluable. At the time of analysis, 30 patients were alive with a median follow-up of 30 months. The 3-year probability of overall survival (OS) was 15% (95% confidence interval [CI], 10-20). The cumulative incidence of relapse at 3 years was 49% (95% CI, 42-56). Notably, almost 70% of all relapses occurred within the first 6 months after HSCT. Patients who were transplanted in first complete remission (CR1) had superior OS compared with those with advanced disease (22% vs 9%, P < .001). Our findings confirm the high-risk of treatment failure in abnl(17p) AML even after allogeneic HSCT in CR1. Although allogeneic HSCT remains a valid option in CR1, alternative treatment strategies are needed for the remaining patients. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
7. Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial
- Author
-
Bornhäuser, Martin, Kienast, Joachim, Trenschel, Rudolf, Burchert, Andreas, Hegenbart, Ute, Stadler, Michael, Baurmann, Herrad, Schäfer-Eckart, Kerstin, Holler, Ernst, Kröger, Nicolaus, Schmid, Christoph, Einsele, Herrmann, Kiehl, Michael G, Hiddemann, Wolfgang, Schwerdtfeger, Rainer, Buchholz, Stefanie, Dreger, Peter, Neubauer, Andreas, Berdel, Wolfgang E, and Ehninger, Gerhard
- Subjects
- *
ACUTE myeloid leukemia , *CELL transplantation , *CLINICAL trials , *FLUDARABINE , *CYCLOPHOSPHAMIDE , *GRAFT versus host disease - Abstract
Summary: Background: Reduced-intensity conditioning regimens have been developed to minimise early toxic effects and deaths after allogeneic haemopoietic cell transplantation. However, the efficacy of these regimens before this procedure has not been investigated in a randomised trial. In this prospective, open-label randomised phase 3 trial we compared a reduced-intensity fludarabine-based conditioning regimen with a standard regimen in patients with acute myeloid leukaemia in first complete remission. Methods: Patients were aged 18–60 years and had intermediate-risk or high-risk acute myeloid leukaemia (defined by cytogenetics) in first complete remission; an available HLA-matched sibling donor or an unrelated donor with at least nine of ten HLA alleles; and adequate renal, cardiac, pulmonary, and neurological function. Between Nov 15, 2004, and Dec 31, 2009, patients were randomly assigned (1:1, by a computer-based minimisation procedure that balanced patients for age, cytogenetic risk, induction therapy, and donor type) to receive either reduced-intensity conditioning of four doses of 2 Gy of total-body irradiation and 150 mg/m2 fludarabine or standard conditioning of six doses of 2 Gy of total-body irradiation and 120 mg/kg cyclophosphamide. All patients were given ciclosporin and methotrexate as prophylaxis against graft-versus-host disease. Neither investigators nor patients were blinded to study treatment. Our primary endpoint was the incidence of non-relapse mortality, analysed in the intention-to-treat population. The trial is registered with ClinicalTrials.gov, number NCT00150878. Findings: The trial was stopped early on Dec 31, 2009, because of slow accrual of patients. 99 patients were randomly assigned to receive reduced-intensity conditioning and 96 to receive standard conditioning. The incidence of non-relapse mortality did not differ between the reduced-intensity and standard conditioning groups (cumulative incidence at 3 years 13% [95% CI 6–21] vs 18% [10–26]; HR 0·62 [95% CI 0·30–1·31]). Relapse incidence (cumulative incidence 3 years 28% [95% CI 19–38] vs 26% [17–36]; HR 1·10 [95% CI 0·63–1·90]), disease-free survival (3 year disease-free survival 58% [95% CI 49–70] vs 56% [46–67]; HR 0·85 [95% CI 0·55–1·32]), and overall survival (3 year overall survival 61% [95% CI 50–74] vs 58% [47–70]; HR 0·77 [95% CI 0·48–1·25]) did not differ significantly between groups. Grade 3–4 of oral mucositis was less common in the reduced-intensity group than in the standard conditioning group (50 patients in the reduced-intensity conditioning group vs 73 patients in the standard conditioning group); the frequency of other side-effects such as graft-versus-host disease and increased concentrations of bilirubin and creatinine did not differ significantly between groups. Interpretation: Reduced-intensity conditioning results in a similar incidence of non-relapse mortality and reduced toxic effects compared with standard conditioning without affecting survival outcomes, and thus could be preferentially used in patients younger than 60 years with acute myeloid leukaemia transplanted in first complete remission. Funding: Medical Faculty of Dresden University. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
8. Outcome of high-risk acute myeloid leukemia after allogeneic hematopoietic cell transplantation: negative impact of abnl(17p) and -- 5/5q-.
- Author
-
Middeke, Jan M., Beelen, Dietrich, Stadler, Michael, Göhring, Gudrun, Schlegelberger, Brigitte, Baurmann, Herrad, Bug, Gesine, Beilos, Frauke, Mohr, Brigitte, Buchholz, Stefanie, Schwerdtfeger, Rainer, Martin, Hans, Hegenbart, Ute, Ehninger, Gerhard, Bornhäuser, Martin, and Schetelig, Johannes
- Subjects
- *
ACUTE myeloid leukemia , *HEMATOPOIETIC stem cells , *KARYOTYPES , *CHROMOSOME abnormalities , *PRECANCEROUS conditions , *BONE marrow cells - Abstract
The European LeukemiaNet classification combines a heterogeneous group of aberrations as adverserisk abnormalities. Our goal was to investigate the outcomes associated with distinct highrisk chromosomal abnormalities in acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (HSCT). We performed a retrospective cohort analysis in patients with highrisk AML who received first, HLA-compatible, allogeneic HSCT between January 2005 and December 2008. Data from 236 patients with a median age of 55 years were included. Because complex karyotype (CK), -5/5q--, and abnl(17p) are overlapping categories, a hierarchical classification system based on the presence or absence of abnl(17p) and -5/5q- was developed. Patients with abnl(17p) had a 2-year eventfree survival (EFS) of 11% (95% confidence interval [CI], 0%-25%), patients with -5/5q- but no abnl(17p) a 2-year EFS of 29% (95% CI, 14%-44%), and patients with adverserisk AML but neither of the 2 marker lesions a 2-year EFS of 49% (95% CI, 39%-59%). Notably, complex and monosomal karyotypes lost their prognostic value when these marker lesions were excluded. In conclusion, hierarchical classification of adverserisk karyotypes by 2 marker lesions, abnl(17p) and -5/5q-, is effective In prognostication of the outcome of allogeneic HSCT in AML. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.